Well, this week was a OBO start : at www.otcbb.com
Price Qty Time
↑ 0.750 500 07/08/04
0.500 2500 07/08/04
0.500 500 07/08/04
0.500 2000 07/07/04
0.500 2000 07/07/04
If that doesn't say something on a new stock, what does. The TREND IS YOUR FRIEND as we all know in any TRADING. Get with the PROGRAM. Now say PROGRAM TRADING, or PROGRAMED TRADING as QBIT with show us how.
Pinks Sheets Company Info Page:
Houston
TX 77042
USA
Phone: 713-784-7132
Company Website: quantumbit.com
Officers:
Mike Skillern Pres.; Ellis Gibson, Treas.; Pete McCain, Sec't.
Shares Outstanding: 50,000,000 as of 2004-03-31
Estimated Market Cap: 37.5M as of 2004-07-08
Current Capital Change: None
Dividends: None
State of Incorporation: NV
Transfer Agents:
Nevada Agency & Trust Co., Reno, NV 98501
Houston Texas is the Home, go Roger Clemmens and be a ROCKET again and again. Just like QUANTUM BIT can.
I talked to Mike when a few years ago i invested in BIOTECHS: look what I got here from 5 years ago:
cytogenix.com
: August 1999« Back
Dr. Skolnick to Take CYGS Helm
HOUSTON, TEXAS (August 9, 1999). Cryogenic Solutions, Inc. (OTC BB: CYGS) announced today that Malcolm Skolnick, PhD, JD will assume the duties of President and CEO on September first. Dr. Skolnick has previously served the company as a member of the board of directors and is currently of counsel to the company and Chairman of the Scientific Advisory Board.
Current president and founder, Mike Skillern will return to applying full time to technology development. "I've been working hard to get Dr. Skolnick on board as CEO so I can get back to what I do best." Said Skillern. "Dr. Skolnick has exactly the right set of skills and experience to establish our single stranded DNA expression vector as the antisense delivery platform, much like an operating system, that will enable gene therapy to become a practical reality." Skillern, whose principal field of interest is quantum mechanics, is pursuing a number of applications and patents of quantum state induction technologies, including induction control of biochemical processes.
Although in recent years Dr. Skolnick's academic career has been in medicine and biotechnology, he earned his PhD in Theoretical Nuclear Physics at Cornell University in 1963 and was a Member of the School of Mathematics at the Institute for Advanced Study, Princeton, New Jersey.
Beginning in 1971 at the University of Texas Health Science Center, Dr. Skolnick served in various capacities including Professor of Biophysics, Director of the Neurophysiology Research Center, Director of the Office of Technology Management, and Professor of Technology and Health Law at the School of Public Health. He has conducted clinical trials related to pain management and detoxification from addictive drugs and holds patents on the devices developed in the research that led to those trials. Current teaching activities include "The Food and Drug Administration" and "Healthcare Technology Assessment".
Additionally, Dr. Skolnick earned a JD in 1986 at University of Houston School of Law and is a practicing patent attorney. His legal activities have included appearances before and submissions to the FDA, patent prosecution of US and foreign cases, and the drafting and negotiation of contracts and license agreements to facilitate technology transfer for commercialization of intellectual property.
This background uniquely qualifies Dr. Skolnick to help Mr. Skillern develop the technologies where Medicine and Physics intersect and it provides an invaluable perspective to the new leadership of CYGS.
CYGS has developed an effective delivery mechanism for anti-sense oligodeoxyribonucleotides (ODN's). Combination of the CYGS single stranded DNA expression vector with the appropriate ODN for a specific disease or condition has been demonstrated in the laboratory.
Dr. Skolnick explained, "I believe the antisense technology heralds a paradigm shift from the chemical treatment of symptoms to the biopharmaceutical elimination of disease, and the CYGS vector is pivotal to the successful implementation of the technology."
"Molecular biology has brought a new dimension to medical science. The technology is constantly offering new methods to combat disease and extend life. Medical problems ranging from curing or preventing virus infections or cancer to methods which slow the aging process are being studied by delivering oligonucleotide sequences to the diseased or senescent cell. "
Dr. Skolnick continued, "The impact of this technology on medical and pharmaceutical practice is already being felt. As the new anti-sense technology emerges from the laboratory and into clinical trials questions about regulation and delivery of the new medications must be addressed. Prescription of these new kinds of medication by physicians depends as always on the physician's knowledge of the underlying science and how that may be used for the benefit of the patient. "
"The CYGS expression vector technology can be utilized with virtually any ODN that has been demonstrated effective in a particular cellular application. The expression vector by itself is a neutral quantity. Pharmaceutically speaking, it is an excipient, that is a neutral substance used to deliver an active compound."
Dr. Skolnick concluded, "Our company is at the triple threshold of assisting inventors demonstrating clinical effectiveness of their ODN's with our expression vector, achieving regulatory approval for a given ODN/vector combination, and finding a way to provide that therapeutic combination to patients. I see my role in CYGS as guiding the Company in crossing these thresholds. "
Dr. Skolnick's full CV is available in the company's website, www.cygs.net . ( Changed Now )
Contradus from Chucka...it took til now - we fly above the 44 cents on CYGX that we watched grow also, that rhymes - so does QBIT the ORBIT is SOWED as we watch the quantum bits grow.! 5 years reaping, not bad MIKES |
